Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
As of close of business last night, Zai Lab Limited ADR’s stock clocked out at $14.22, up 3.64% from its previous closing price of $13.72. In other words, the price has increased by $3.64 from its previous closing price. On the day, 0.69 million shares were traded. ZLAB stock price reached its highest trading level at $14.23 during the session, while it also had its lowest trading level at $13.48.
Ratios:
To gain a deeper understanding of ZLAB’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.41 and its Current Ratio is at 4.63. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on December 14, 2023, initiated with a Overweight rating and assigned the stock a target price of $47.50.
On August 10, 2023, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $70.
On January 21, 2022, Macquarie started tracking the stock assigning a Outperform rating and target price of $64.Macquarie initiated its Outperform rating on January 21, 2022, with a $64 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 04 ’24 when Reinhart Harald sold 2,105 shares for $15.67 per share. The transaction valued at 32,992 led to the insider holds 51,800 shares of the business.
Smiley Joshua L sold 1,988 shares of ZLAB for $31,158 on Apr 04 ’24. The insider now owns 28,684 shares after completing the transaction at $15.67 per share. On Apr 04 ’24, another insider, Amado Rafael, who serves as the insider of the company, sold 1,952 shares for $15.67 each. As a result, the insider received 30,594 and left with 23,532 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZLAB now has a Market Capitalization of 1410747776 and an Enterprise Value of 13246331904. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.26 while its Price-to-Book (P/B) ratio in mrq is 1.74. Its current Enterprise Value per Revenue stands at 49.664 whereas that against EBITDA is -36.04.
Stock Price History:
Over the past 52 weeks, ZLAB has reached a high of $39.50, while it has fallen to a 52-week low of $13.66. The 50-Day Moving Average of the stock is -21.48%, while the 200-Day Moving Average is calculated to be -41.04%.
Shares Statistics:
It appears that ZLAB traded 683.67K shares on average per day over the past three months and 499570 shares per day over the past ten days. A total of 98.72M shares are outstanding, with a floating share count of 98.31M. Insiders hold about 0.41% of the company’s shares, while institutions hold 42.51% stake in the company. Shares short for ZLAB as of 1711584000 were 3867366 with a Short Ratio of 5.66, compared to 1709164800 on 4063914.
Earnings Estimates
The current rating of Zai Lab Limited ADR (ZLAB) reflects the combined expertise of Astera Labs, Inc. analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is $14.22, with high estimates of $26.09 and low estimates of $117.50.
Analysts are recommending an EPS of between $Technology and $Technology for the fiscal current year, implying an average EPS of $Healthcare.
